Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Related Keywords

Copenhagen ,Køavn ,Denmark ,United States ,Switzerland ,America ,Robertj Deluccia ,Ursula Theuretzbacher ,Kevin Garey ,Data Monitoring Committee ,Company Ph ,Drug Administration ,University Of Houston ,Exchange Commission On Form ,Society Or Healthcare Epidemiology Of America ,Infectious Diseases Society Of America ,European Society Of Clinical Microbiology ,Research Scientist Faculty ,Acurx Pharmaceuticals Inc ,Acurx Pharmaceuticals ,University Of Houston College Pharmacy ,Trial Oversight Committee ,Exchange Commission ,European Congress ,Prnewswire Acurx Pharmaceuticals Inc ,Nasdaq ,Lead Optimization ,Annual European Congress ,Clinical Microbiology ,Infectious Disease ,Ibezapolstat Against ,Reduced Susceptibility ,Houston College ,Principal Investigator ,Acurx Executive Chairman ,Gram Positive Selective Spectrum ,Independent Data Monitoring Committee ,Investigational New Drug Application ,Qualified Infectious Disease Product ,Generating New Antibiotic Incentives Now ,Infectious Diseases ,European Society ,Executive Committee ,Clinical Practice ,Infectious Diseases Society ,Healthcare Epidemiology ,New England Journal ,New England ,Scientific Advisory Board ,Private Securities Litigation Reform Act ,Nc ,